Live vaccines have a long history for providing efficient protection against subsequent infectious challenge. However, the mechanisms leading to protection are in many cases not well defined. Our goal is to define mechanisms for immune protection by Gram-negative bacterial vaccine strains, using novel Yersinia pestis strains as model systems. The gram-negative bacterium Yersinia pestis is the causative agent of plague. Currently there is no available licensed plague vaccine, and exploratory vaccines have variable ability to protect against pneumonic disease, the form expected after a bioterror attack. We have developed a new method for the generation of efficient vaccine strains for protection against plague and potentially other microorganisms, based upon enhancement of inherent bacterial Toll-like receptor (TLR)-4 mediated adjuvant activity. Similar to various other gram-negative bacteria, Y. pestis produces a lipopolysaccharide (LPS) with low stimulatory ability at 37:C. TLR4 is the cellular receptor for LPS via its lipid A. We generated a new Y. pestis strain expressing LpxL, an E. coli lipid A biosynthesis enzyme, and found this to produce a potent LPS at 37:C. This strain is avirulent in mice by peripheral inoculation, due to induction of antibacterial innate immune mechanisms via TLR4, a pathway also associated with strong adjuvant effects. Our results indicate that vaccination of mice with the Y. pestis LpxL strain induces full protection against both subcutaneous and intranasal challenge of mice with virulent bacteria, mimicking bubonic and pneumonic plague. Our main hypotheses are that many live bacterial vaccine strains containing LPS with increased potency are efficient vaccines, and that the increased TLR4 signaling will provide enhanced adaptive immune responses. We propose to determine mechanisms influencing the vaccine efficacy using live and killed Y. pestis producing a potent LPS, by comparing to strains without increased TLR4 stimulation, testing both in vitro and in vivo responses. Both existing and novel attenuated strains will be used. Relying on primary dendritic and T cells and genetically deficient mice, we will study TLR signaling pathways leading to dendritic cell activation in vivo and in vitro, antigen presentation and T cell subset activation. We will analyze vaccine effects against both subcutaneous and intranasal infection. The completion of these studies will provide information on the mechanism by which vaccine strains towards Gram-negative infections may act. Incorporation of TLR- stimulating adjuvant activity directly into immune-evading pathogens may constitute a novel method for attenuation and generation of vaccines.

Public Health Relevance

This proposal will identify mechanisms by which live vaccines against some bacterial infections work. We will use novel avirulent, immunostimulatory strains of the plague bacillus Yersinia pestis as a model system. Our results may help in the design of future vaccines against plague and other infectious diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI075318-01A2
Application #
7655827
Study Section
Immunity and Host Defense Study Section (IHD)
Program Officer
Zou, Lanling
Project Start
2009-04-01
Project End
2014-03-31
Budget Start
2009-04-01
Budget End
2010-03-31
Support Year
1
Fiscal Year
2009
Total Cost
$235,601
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Type
Organized Research Units
DUNS #
603847393
City
Worcester
State
MA
Country
United States
Zip Code
01655
Marty-Roix, Robyn; Lien, Egil (2013) (De-) oiling inflammasomes. Immunity 38:1088-90
Vladimer, Gregory I; Marty-Roix, Robyn; Ghosh, Shubhendu et al. (2013) Inflammasomes and host defenses against bacterial infections. Curr Opin Microbiol 16:23-31
Vladimer, Gregory I; Weng, Dan; Paquette, Sara W Montminy et al. (2012) The NLRP12 inflammasome recognizes Yersinia pestis. Immunity 37:96-107
Meng, Jianmin; Lien, Egil; Golenbock, Douglas T (2010) MD-2-mediated ionic interactions between lipid A and TLR4 are essential for receptor activation. J Biol Chem 285:8695-702
Duewell, Peter; Kono, Hajime; Rayner, Katey J et al. (2010) NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464:1357-61
He, Xianbao; Mekasha, Samrawit; Mavrogiorgos, Nikolaos et al. (2010) Inflammation and fibrosis during Chlamydia pneumoniae infection is regulated by IL-1 and the NLRP3/ASC inflammasome. J Immunol 184:5743-54
Nguyen, Thuy Thanh; Johnsen, Ingvild B; Knetter, Cathrine F et al. (2010) Differential gene expression downstream of Toll-like receptors (TLRs): role of c-Src and activating transcription factor 3 (ATF3). J Biol Chem 285:17011-9
Husebye, Harald; Aune, Marie Hjelmseth; Stenvik, Jorgen et al. (2010) The Rab11a GTPase controls Toll-like receptor 4-induced activation of interferon regulatory factor-3 on phagosomes. Immunity 33:583-96
Szaba, Frank M; Kummer, Lawrence W; Wilhelm, Lindsey B et al. (2009) D27-pLpxL, an avirulent strain of Yersinia pestis, primes T cells that protect against pneumonic plague. Infect Immun 77:4295-304